Tenidap: A Novel Cytokine-modulating Antirheumatic Drug for the Treatment of Rheumatoid Arthritis

References

• Veys E M, Mielants H, Verbruggen G, De Keyser F. Intervention with immunomodulatory agents: new pharmacological developments, P Emery. Ballieres Tindall, London 1992; 6: 455–84, Clin Rheumatol
   Google Scholar
• Harris ED, Jr. Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med 1990; 322: 1277–89
   PubMed Web of Science ®Google Scholar
• Dingle J T. Recent studies on the control of joint damage. Ann Rheum Dis 1979; 38: 201–14
   PubMed Web of Science ®Google Scholar
• Peltipher E R, Higgs G A, Henderson B. Interleukin-1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint. Proc Natl Acad Sci USA 1986; 83: 874–953
   Web of Science ®Google Scholar
• Van den Berg W, Joosten L AB, Helsen M. Suppressive effect of CP-66,248 on murine antigen-induced arthritis. Arthritis Rheum 1989; 32(4)S52
   Google Scholar
• Darlington G J, Wilson D R, Lachman L B. Monocyte conditioned medium, interleukin 1 and tumour necrosis factor stimulate the acute phase response in human heptoma cell lines in vitro. J Cell Biol 1986; 103: 787–93
   PubMed Web of Science ®Google Scholar
• Andus T, Geiger T, Hirano T, Kishimoto T, Tran-Thi T-A, Decker K. Regulation of synthesis and secretion of major rat acute-phase proteins by recombinant human interleukin-6 (BSF-2/IL-6) in hepatocyte primary cultures. Eur J Biochem 1988; 173: 287–93
   PubMedGoogle Scholar
• Gauldie J, Richards C, Hamish D, Lansdorp P, Baumann H. Interferon beta 2/B cell stimulatory factor type-2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci USA 1987; 84: 7251–5
   PubMed Web of Science ®Google Scholar
• Fey G H, Fuller G M. Regulation of acute phase gene expression by inflammatory mediators. Mol Biol Med 1987; 4: 323–8
   PubMedGoogle Scholar
• Hirano T, Akira S, Taga T, Kishimoto T. Biological and clinical aspects of IL-6. Immunol Today 1990; 11: 443–9
   PubMedGoogle Scholar
• Houssiau F A, Devogelaer J-P, Van Damme J, De Deuxchaisnes C N, Van Snick J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 1988; 31: 784–8
   PubMed Web of Science ®Google Scholar
• Emery P, Luqmani R. The validity of surrogate markers in rheumatic disease. Br J Rheumatol 1993; 32(3)3–8
   PubMedGoogle Scholar
• McConkey B, Crockson R A, Crockson A P. The assessment of rheumatoid arthritis. A study based on the measurement of the serum acute phase reactants. Q J Med XLI 1972; 162: 115–25
   Google Scholar
• McConkey B, Crockson R A, Crockson A P, Wilkinson A R. The effects of some anti-inflammatory drugs on the acute-phase proteins in rheumatoid arthritis. Q J Med XLII 1973; 168: 785–91
   Google Scholar
• Mallya R K, De Beer F C, Berr H, Hamilton E DB, Mace B EW, Pepys M. Correlation of clinical parameters of disease activity in rheumatoid arthritis with serum concentration of C-reactive protein and erythrocyte sedimentation rate. J Rheumatol 1982; 9: 3224–8
   Web of Science ®Google Scholar
• Amos R S, Constable T J, Crockson RA, Crockson A P, McConkey B. Rheumatoid arthritis: relation to serum C-reactive protein and erythrocyte sedimentation rates to radiographic changes. Br Med J- 1977; i: 195–7
   Google Scholar
• Ballou S P, Kushner I. C-reactive protein and the acute phase response. Adv Intern Med 1992; 37: 313–6
   PubMedGoogle Scholar
• Hart W R. C-reactive protein: the best laboratory indicator available for monitoring disease activity. Cleve Clin J Med 1989; 56: 126–30
   PubMed Web of Science ®Google Scholar
• Dawes P T, Fowler P D, Clarke S, Fisher J, Lawton A, Shadforth M F. Rheumatoid arthritis: treatment which controls the C-reactive protein and erythrocyte sedimentation rate reduces radiological progression. Br J Rheumatol 1986; 25: 44–9
   PubMedGoogle Scholar
• Larsen A. The relation of radiographic changes to serum acute-phase proteins and rheumatoid factor in 200 patients with rheumatoid arthritis. Scand J Rheumatol 1988; 17: 123–9
   PubMed Web of Science ®Google Scholar
• Van der Heijde D MFM, Van Riel P LCM, Van Leewuen M A, Van't Hof M A, Van Rijswijk M H, Van de Putte L BA. Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients. Br J Rheumatol 1992; 31: 519–25
   PubMedGoogle Scholar
• Van Leeuwen M A, Van Rijswijk M H, Van der Heijde D MFM, Te Meerman G J, Van Riel P LCM, Houtman P M. The acute-phase response in relation to radiographic progression in early rheumatoid arthritis: A prospective study during the first three years of the disease. Br J Rheumatol 1993; 32(3)9–13
   PubMedGoogle Scholar
• Menkes C-J. Effects of disease-modifying anti-rheumatic drugs steroids and non-steroidal anti-inflammatory drugs on acute-phase proteins in rheumatoid arthritis. Br J Rheumatol 1993; 32: 14–8
   PubMedGoogle Scholar
• Otterness I G, Bliven M L, Downs J T, Natoli E J, Hanson D C. Inhibition of interleukin 1 synthesis by tenidap: A new drug for arthritis. Cytokine 1991; 3(4)277–83
   PubMed Web of Science ®Google Scholar
• Otterness I G, Bliven M L, Eskra J, Reinke M, Hanson D C. The pharmacologic regulation of IL-1 production. The role of prostaglandins. Cell Immunol 1988; 114: 385–97
   PubMed Web of Science ®Google Scholar
• Gabel C A, McNiff P, Perrigaux D, Svensson L, Pazoles C J. Tenidap inhibits anion transport in vitro. Arthritis Rheum 1993; 36(9)109
   Google Scholar
• Sipe J D, Bartle L M, Loose L D. Modification of proinflammatory cytokine production by the antirheumatic agents tenidap and naproxen. A possible correlate with clinical acute phase response. J Immunol 1992; 148: 480–4
   PubMed Web of Science ®Google Scholar
• Pazoles C J, McNiff P, Laliberte R, Gabel C A. Tenidap acts in vitro as an antagonist of cytokine-induced functions. Arthritis Rheum 1993; 36: 109
   Google Scholar
• Otterness I G, Carty T J, Loose L D. Tenidap: a new drug for arthritis. Therapeutic approaches to inflammatory disease, AJ Lewis, NS Doherty, NR Ackerman. Elsevier, New York 1989; 229–41
   Google Scholar
• Dingle J T. The effect of synovial catabolism on cartilage synthetic activity. Connect Tissue Res 1984; 12: 277–86
   PubMed Web of Science ®Google Scholar
• Dingle J T, Leeming M RG, Martindale J J. Effect of tenidap on cartilage integrity in vitro. Ann Rheum Dis 1993; 52: 292–9
   PubMed Web of Science ®Google Scholar
• Blackburn W D, Loose L D, Chatham W W. Tenidap enhances basal chondrocyte proteoglycan synthesis and reverses IL-1 induced effects. Arthritis Rheum 1994, (in press)
   Google Scholar
• Pelletier J-P, McCollum R, DiBattista J, Loose L D, Cloutier J-M, Martel-Pelletier J. Regulation of human normal and osteoarthritic chondrocyte interleukin-1 receptor by antirheumatic drugs. Arthritis Rheum 1993; 36: 1–11
   PubMed Web of Science ®Google Scholar
• Chandrasekhar S, Harvey A K. Induction of interleukin-1 receptors on chondrocytes by fibroblast growth factor: a possible mechanism for modulation of interleukin-1 activity. J Cell Physiol 1989; 138: 236–46
   PubMed Web of Science ®Google Scholar
• Martel-Pelletier J, McCollum R, Tardif G, Mineau F, Cloutier J M, Pelletier J-P. Tenidap, a new antirheumatic drug, reduces IL-1R expression and IL-1-induced expression of metalloproteases in human cartilage chondrocytes. Arthritis Rheum 1992; 35: 131
   Google Scholar
• Smith R J, Justen J M, Sam L M, Rohloff N A, Ruppel P L, Brunden M N. Platelet-derived growth factor potentiates cellular responses of articular chondrocytes to interleukin-1. Arthritis Rheum 1991; 34: 697–706
   PubMed Web of Science ®Google Scholar
• Blackburn W D, Loose L D, Heck L W, Chatham W W. Tenidap, in contrast to several available nonsteroidal antiinflammatory drugs, potently inhibits the release of activated neutrophil collagenase. Arthritis Rheum 1991; 34: 211–6
   PubMed Web of Science ®Google Scholar
• Al Humidan A M, Reilly K M, Leeming M RG, Russell R GG. Tenidap inhibits bone resorption induced by PTH, 1,25 Vit D3, IL-1,TNF and PGE2in vitro by mechanisms independent of inhibition of prostaglandin synthesis. Arthritis Rheum 1991; 34: 192
   PubMed Web of Science ®Google Scholar
• Littman B H, Carlson P L, Loose L D, Sanders K M. Effects of gold sodium thiomalate and tenidap sodium (CP-66, 248–2) on a model of macrophage differentiation using HL-60 cells. Arthritis Rheum 1990; 33: 29–36
   PubMed Web of Science ®Google Scholar
• Kyan-Aung U, Lee T H, Haskard D O. The inhibitory effect of tenidap on leukocyte endothelial cell adhesion. J Rheumatol 1993; 20: 1014–9
   PubMed Web of Science ®Google Scholar
• Tonneson M G, Anderson D C, Springer T A, Knedler A, Avdi N, Henson P M. Adherence of neutrophils to cultured human microvascular endothelial cells. J Clin Invest 1989; 83: 637–46
   PubMed Web of Science ®Google Scholar
• Smith C W, Marlin S D, Rothlein R, Toman C, Anderson D C. Cooperative interactions of LFA-1 and Mac-1 with intercellular adhesion molecule-1 in facilitating adherence and transendothelial migration of human neutrophils in vitro. J Clin Invest 1989; 83: 2008–17
   PubMed Web of Science ®Google Scholar
• Carty T J, Showell H J, Loose L D, Kadin S B. Inhibition of both 5-lipoxygenase (5-LO) and cyclo-oxygenase (CO) pathways of arachidonic acid metabolism by CP-66, 248, a novel anti-inflammatory compound. Arthritis Rheum 1988; 31: 89, Suppl. 4
   Google Scholar
• Moilanen E, Alanko J, Asmawi M Z, Vapaatalo H. CP-66,248, a new anti-inflammatory agent, is a potent inhibitor of leukotriene B4 and prostanoid synthesis in human polymorphonuclear leukocytes in vitro. Eicosanoids 1988; 1: 35–9
   PubMedGoogle Scholar
• Blackburn W D, Heck L W, Loose L D, Eskra J D, Carty T J. Inhibition of 5-lipoxygcnase product formation and polymorphonuclear cell degranulation by tenidap sodium in patients with rheumatoid arthritis. Arthritis Rheum 1991; 34: 204–9
   PubMed Web of Science ®Google Scholar
• Loose L D, Weiner E S, Kirby D S, Wilhelm F E, Shanahan W R. Tenidap vs naproxen vs placebo in rheumatoid arthritis (RA): A 2-week study in patients with knee effusions. Arthritis Rheum 1994, (in press)
   Google Scholar
• Otterness I G, Pazoles P P, Moore P F, Pepys M B. C-reactive protein as an index of disease activity. Comparison of tenidap cyclophosphamide and dexamethasone in rat adjuvant arthritis. J Rheumatol 1991; 18(4)505–11
   PubMed Web of Science ®Google Scholar
• Loose L D, Wilhelm F E, Kraska A R, Kirby D S, Ting N, Shanahan W R. Double-blind placebo-controlled dose response study of tenidap in rheumatoid arthritis. Arthritis Rheum 1993; 36: 166
   Google Scholar
• Loose L D, Sipe J D, Kirby D S, Kraska A R, Weiner E S, Shanahan W R. Reduction of acute-phase proteins with tenidap sodium a cytokine-modulating antirheumatic drug. Br J Rheumatol 1993; 32: 19–25
   PubMedGoogle Scholar
• Felson D T, Anderson J J, Boers M, Bombardier C, Chernoff M, Fried B. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993; 36(6)729–40
   PubMed Web of Science ®Google Scholar
• Wylie G. A 24 week study of tenidap vs diclofenac in rheumatoid arthritis. Rev Esp Reumatol 1993; 20(1)A306
   Google Scholar
• Kraska A R, Kirby D S, Loose L D, Shanahan E S, Weiner E S, Ting N. Comparison of tenidap, piroxicam and the combination of piroxicam and hydroxychloroquine in the treatment of rheumatoid arthritis. Rev Esp Reumatol 1993; 20: Th80
   Google Scholar
• Leeming M RG. A double-blind randomised comparison of tenidap versus auranofin plus diclofenac in early rheumatoid arthritis (RA). Rev Esp Reum 1993; 20(1): Th189
   Google Scholar
• Kraska A R, Wilhelm F E, Kirby D S, Loose L D, Ting N, Shanahan W R. Tenidap vs piroxicam vs piroxicam plus hydroxychloroquine in rheumatoid arthritis. Arthritis Rheum 1993; 36: 57
   Google Scholar
• Littman B H, Drury C E, Stewart C R. Cytokine modulation: The effects of tenidap a novel approach to the treatment of arthritis. Rev Esp Reumatol 1993; 20: 287–8
   Google Scholar
• Kirby D S, Loose L D, Weiner E S, Wilhelm F E, Shanahan W R, Ting N. Tenidap vs naproxen treatment of rheumatoid arthritis (RA). Arthritis Rheum 1993; 36: 112
   Google Scholar
• McDonald B, Loose L, Rosenwasser L I. Synovial fluid IL-1 in RA patients receiving a novel arachidonate inhibitor CP-66,248. Arthritis Rheum 1988; 31(4)A88
   PubMed Web of Science ®Google Scholar